Twinbeech Capital LP Immunovant, Inc. Transaction History
Twinbeech Capital LP
- $5.52 Billion
- Q4 2024
A detailed history of Twinbeech Capital LP transactions in Immunovant, Inc. stock. As of the latest transaction made, Twinbeech Capital LP holds 12,689 shares of IMVT stock, worth $349,074. This represents 0.01% of its overall portfolio holdings.
Number of Shares
12,689Holding current value
$349,074% of portfolio
0.01%Shares
4 transactions
Others Institutions Holding IMVT
# of Institutions
218Shares Held
67.1MCall Options Held
2.48MPut Options Held
561K-
Vanguard Group Inc Valley Forge, PA6.68MShares$184 Million0.0% of portfolio
-
Deep Track Capital, LP Greenwich, CT6MShares$165 Million7.27% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD5.12MShares$141 Million0.08% of portfolio
-
Black Rock Inc. New York, NY4.92MShares$135 Million0.0% of portfolio
-
Armistice Capital, LLC New York, NY3.87MShares$106 Million1.5% of portfolio
About Immunovant, Inc.
- Ticker IMVT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 129,077,000
- Market Cap $3.55B
- Description
- Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of mya...